Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment is a research paper published in Cancers (2022). On theSindex it has a DataRank of 0. It has been cited 8 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Cancer Prevention and Research Institute of Texas
Grant: RP100406
Cancer Prevention and Research Institute of Texas
Grant: RP140399
Cancer Prevention and Research Institute of Texas
Grant: 5R01 CA140674
Cancer Prevention and Research Institute of Texas
Grant: 1R01 CA244579-01A1
Cancer Prevention and Research Institute of Texas
Grant: 1S10 RR024757
Cancer Prevention and Research Institute of Texas
Grant: P30 CA142543
NCRR NIH HHS
Grant: S10 RR024757
NCI NIH HHS
Grant: R01 CA140674
NCI NIH HHS
Grant: R01 CA244579
National Institutes of Health
Grant: 5R01CA140674-05
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment
National Institutes of Health
Grant: 1S10RR024757-01
Small Animal Bioluminescence and Fluorescence Imaging System (with 3D capability)
National Institutes of Health
Grant: 5R01CA244579-04
Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer
National Institutes of Health
Grant: 3P30CA142543-12S1
Multidimensional single-cell approach probing HIV-1 integration association with non-AIDS defining cancers (Biospecimens/Biocohort)
Mateon Therapeutics, Inc.
National Institutes of Health
FWCI
0.50
Citation Percentile
0.5%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals